Tags

Type your tag names separated by a space and hit enter

Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Ann Clin Lab Sci. 2007 Spring; 37(2):127-34.AC

Abstract

Previously, we showed that pure ductal carcinoma in situ (DCIS) of the breast can be divided into 3 subtypes (luminal, basal/stem, and null) based on the expression of 5 cytokeratin (CK) markers: CK5/6, CK14, CK17 (stem/basal), and CK8, CK18 (luminal). The distributions of CK subtypes were associated with nuclear grade and differential expression of estrogen receptor-alpha (ER-alpha), progesterone receptor (PR), HER-2/neu, and epidermal growth factor receptor (EGFR). In this study, we further explore the expression patterns of CK markers, ER-alpha, PR, HER-2/neu, and EGFR by immunohistochemical (IHC) analysis of 99 cases of pure DCIS and 96 cases of DCIS with co-existing invasive ductal carcinoma (DCIS/IDC). We show that between high-grade DCIS and DCIS/IDC, there are differential expression patterns for ER-alpha, PR, and EGFR in corresponding CK subtypes, suggesting that at least some pure DCIS is molecularly distinct from DCIS/IDC. In most cases there is a high degree of co-expression of these markers between DCIS and the co-existing IDC, suggesting that DCIS is frequently a precursor lesion for co-existing IDC. The rate of discordant expression of these markers is low and is more frequently associated with high-grade carcinoma, suggesting that other molecular pathways also may also be present. There are significant differences in the expression of these molecular markers between high-grade and non-high-grade carcinomas, supporting the view that high-grade and non-high-grade carcinomas of the breast are molecularly distinct entities.

Authors+Show Affiliations

Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17522367

Citation

Steinman, Sharon, et al. "Expression of Cytokeratin Markers, ER-alpha, PR, HER-2/neu, and EGFR in Pure Ductal Carcinoma in Situ (DCIS) and DCIS With Co-existing Invasive Ductal Carcinoma (IDC) of the Breast." Annals of Clinical and Laboratory Science, vol. 37, no. 2, 2007, pp. 127-34.
Steinman S, Wang J, Bourne P, et al. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Ann Clin Lab Sci. 2007;37(2):127-34.
Steinman, S., Wang, J., Bourne, P., Yang, Q., & Tang, P. (2007). Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Annals of Clinical and Laboratory Science, 37(2), 127-34.
Steinman S, et al. Expression of Cytokeratin Markers, ER-alpha, PR, HER-2/neu, and EGFR in Pure Ductal Carcinoma in Situ (DCIS) and DCIS With Co-existing Invasive Ductal Carcinoma (IDC) of the Breast. Ann Clin Lab Sci. 2007;37(2):127-34. PubMed PMID: 17522367.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. AU - Steinman,Sharon, AU - Wang,Jianmin, AU - Bourne,Patricia, AU - Yang,Qi, AU - Tang,Ping, PY - 2007/5/25/pubmed PY - 2007/6/15/medline PY - 2007/5/25/entrez SP - 127 EP - 34 JF - Annals of clinical and laboratory science JO - Ann Clin Lab Sci VL - 37 IS - 2 N2 - Previously, we showed that pure ductal carcinoma in situ (DCIS) of the breast can be divided into 3 subtypes (luminal, basal/stem, and null) based on the expression of 5 cytokeratin (CK) markers: CK5/6, CK14, CK17 (stem/basal), and CK8, CK18 (luminal). The distributions of CK subtypes were associated with nuclear grade and differential expression of estrogen receptor-alpha (ER-alpha), progesterone receptor (PR), HER-2/neu, and epidermal growth factor receptor (EGFR). In this study, we further explore the expression patterns of CK markers, ER-alpha, PR, HER-2/neu, and EGFR by immunohistochemical (IHC) analysis of 99 cases of pure DCIS and 96 cases of DCIS with co-existing invasive ductal carcinoma (DCIS/IDC). We show that between high-grade DCIS and DCIS/IDC, there are differential expression patterns for ER-alpha, PR, and EGFR in corresponding CK subtypes, suggesting that at least some pure DCIS is molecularly distinct from DCIS/IDC. In most cases there is a high degree of co-expression of these markers between DCIS and the co-existing IDC, suggesting that DCIS is frequently a precursor lesion for co-existing IDC. The rate of discordant expression of these markers is low and is more frequently associated with high-grade carcinoma, suggesting that other molecular pathways also may also be present. There are significant differences in the expression of these molecular markers between high-grade and non-high-grade carcinomas, supporting the view that high-grade and non-high-grade carcinomas of the breast are molecularly distinct entities. SN - 0091-7370 UR - https://www.unboundmedicine.com/medline/citation/17522367/Expression_of_cytokeratin_markers_ER_alpha_PR_HER_2/neu_and_EGFR_in_pure_ductal_carcinoma_in_situ__DCIS__and_DCIS_with_co_existing_invasive_ductal_carcinoma__IDC__of_the_breast_ L2 - http://www.annclinlabsci.org/cgi/pmidlookup?view=long&pmid=17522367 DB - PRIME DP - Unbound Medicine ER -